Agenus Inc. (NASDAQ:AGEN) shares dropped 6.3% during mid-day trading on Tuesday . The company traded as low as $4.44 and last traded at $4.50, with a volume of 749,535 shares changing hands. The stock had previously closed at $4.80.

AGEN has been the subject of a number of analyst reports. Maxim Group reissued a “buy” rating on shares of Agenus in a report on Wednesday, April 27th. HC Wainwright reissued a “buy” rating on shares of Agenus in a report on Saturday, April 30th. Finally, Zacks Investment Research raised Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $10.47.

The firm’s market capitalization is $417.90 million. The stock’s 50-day moving average price is $4.30 and its 200-day moving average price is $3.80.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, April 28th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.14. Equities analysts predict that Agenus Inc. will post ($1.36) EPS for the current fiscal year.

In other news, CEO Garo H. Armen acquired 100,000 shares of the firm’s stock in a transaction on Monday, May 9th. The shares were purchased at an average cost of $3.18 per share, with a total value of $318,000.00. Following the acquisition, the chief executive officer now directly owns 1,346,026 shares in the company, valued at approximately $4,280,362.68. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.